LON:PRM Proteome Sciences (PRM) Share Price, News & Analysis GBX 1.65 +0.07 (+4.43%) As of 11:55 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About Proteome Sciences Stock (LON:PRM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Proteome Sciences alerts:Sign Up Key Stats Today's Range 1.43▼ 1.6850-Day Range 1.28▼ 2.1752-Week Range 1.20▼ 4.40Volume122,624 shsAverage Volume414,542 shsMarket Capitalization£5.79 millionP/E RatioN/ADividend Yield6.17%Price TargetN/AConsensus RatingN/A Company Overview Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom. Read More Receive PRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteome Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRM Stock News HeadlinesProteome Sciences (LON:PRM) Stock Passes Above Fifty Day Moving Average - Time to Sell?June 30, 2026 | americanbankingnews.comProteome Sciences secures further clinical contractJune 22, 2026 | lse.co.ukJ.P. Morgan is betting on this coinWhile crypto investors panic-sell amid some of the most extreme fear levels since the 2022 bear market… J.P. Morgan (the largest bank on the planet) is quietly building on ONE specific blockchain. Not Bitcoin. Not Ethereum. Not Solana. A coin most retail investors have never heard of. Institutional volume is about to explode. Supply is getting squeezed from both ends. And the coin is currently under $1.00.July 6 at 1:00 AM | Crypto 101 Media (Ad)Proteome Sciences Secures New Chemoproteomics Contract Ahead of Planned 2026 Clinical Programme (PRM)June 22, 2026 | uk.finance.yahoo.comProteome Sciences Wins New Chemoproteomics Contract Ahead of 2026 Trial ProgrammeJune 22, 2026 | tipranks.comProteome Sciences Wins Full Shareholder Backing at AGMMay 14, 2026 | tipranks.comProteome Sciences shares rise as chair hails rebound in businessMay 16, 2025 | lse.co.ukProteome Sciences Full Year 2024 Earnings: UK£0.011 loss per share (vs UK£0.008 loss in FY 2023)April 12, 2025 | finance.yahoo.comSee More Headlines PRM Stock Analysis - Frequently Asked Questions How have PRM shares performed this year? Proteome Sciences' stock was trading at GBX 2.50 at the beginning of 2026. Since then, PRM shares have decreased by 32.8% and is now trading at GBX 1.68. How were Proteome Sciences' earnings last quarter? Proteome Sciences plc (LON:PRM) announced its earnings results on Wednesday, April, 15th. The company reported ($1.04) earnings per share for the quarter. The business had revenue of $3.76 million for the quarter. Proteome Sciences had a negative net margin of 81.50% and a positive trailing twelve-month return on equity of 33.80%. How do I buy shares of Proteome Sciences? Shares of PRM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Proteome Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Proteome Sciences investors own include Lloyds Banking Group (LLOY), Petrofac (PFC), ValiRx (VAL), boohoo group (BOO), Intel (INTC), Mondi (MNDI) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings4/15/2026Today7/06/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryChemicals Current SymbolLON:PRM CIKN/A Webwww.proteomics.com Phone+44-20-70432116FaxN/AEmployees240Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.08 million Net Margins-81.50% Pretax MarginN/A Return on Equity33.80% Return on Assets-19.25% Debt Debt-to-Equity Ratio-165.46 Current Ratio0.13 Quick Ratio0.37 Sales & Book Value Annual Sales£3.76 million Price / Sales1.54 Cash FlowGBX 0.44 per share Price / Cash Flow3.73 Book ValueGBX (1.78) per share Price / Book-0.92Miscellaneous Outstanding Shares350,725,000Free FloatN/AMarket Cap£5.79 million OptionableNot Optionable Beta0.15 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:PRM) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersFINAL HOURS: $9 Income ETF Access VANISHES at MIDNIGHTTim Plaehn's income ETF research service is available at 82% off - but the Independence Day deal expires at mi...Investors Alley | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Midterm Trap That Could Ruin Your 401(k)For investors within 5 to 10 years of retirement, midterm election volatility isn't a distant concern - it's a...American Hartford Gold | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredYou must do this before the OpenAI IPOOpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...InvestorPlace | SponsoredBuy the “unseen winner of the AI race” before July 22Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...Chaikin Analytics | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteome Sciences plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteome Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
